In addition, the company announced that it has received CE-marking for its T-Track® CMV and T-Track® EBV tests following successful clinical validation of both products by measuring functional effector cells of the cell-mediated immune system (CMI) in a cohort of > 120 hemodialysis patients. Observed clinical sensitivities in this patient cohort were 88-100% for T-Track® CMV and 86-97% for T-Track® EBV respectively, depending on the biostatistical method applied. „We are very pleased with the successful completion of these important regulatory milestones which round up our development programs for both tests T-Track® CMV and T-Track® EBV. We now have the tools in place to establish full clinical benefits of these novel T-cell based diagnostics in the field of transplantation and other indications with high medical need” said Dr. Michael Lutz, CEO of Lophius Biosciences.
About Lophius Biosciences
Lophius Biosciences GmbH develops and markets innovative T-cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.
Contact
Lophius Biosciences GmbH
Josef-Engert-Str. 13
D-93053 Regensburg / Germany
Phone: +49 941 6309 1972
E-Mail: info@lophius.de
www.lophius.de
